Divi's Labs tumbles more than 8% after Q2 numbers; here is what analysts have to say

Shares of drug firm Divi's Labs fell more than 8% as analysts forecast rising near-term pressures amid logistical issues, higher raw material prices, and declining generics business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3CVyN90
via IFTTT